COVID-19 и коморбидная патология у детей

Abstract

Objective. To analyze clinical and laboratory characteristics of COVID-19 in children with comorbidities admitted to the intensive care unit (ICU). Patients and methods. This study included 155 infants/children aged 1 month to 18 years with confirmed COVID-19 who were admitted to the ICU No. 2 of Z.A. Bashlyaeva Children's City Clinical Hospital, Moscow Healthcare Department between March 2020 and June 2021. The diagnosis was confirmed by epidemiological, clinical, and laboratory data. Results. Thirty-six out of 155 patients admitted to the ICU (23.2 ± 3.4%) had no comorbidities. Comorbidities were detected in 119 children (76.8±3.4%) with severe COVID-19, which manifested as multisystem inflammatory syndrome in children (MIS-C) (n = 16; 13.4 ± 2.7%), CT 1-2 pneumonia (n = 25; 21 ± 3.3%), CT 2-3 pneumonia (n = 7; 5.9 ± 1.9%), and CT 3-4 pneumonia (n = 19; 16 ± 3.0%). Viral pneumonia with MIS-C was observed in 10 children (8.4 ± 2.2%). Six patients (3.9 ± 1.6%) were diagnosed with generalized bacterial infection, which aggravated the course of COVID-19. Conclusion. A total of 76.8% of children in our study were found to have some comorbidities, which is a risk factor for severe COVID-19. The most common comorbidities included nervous system diseases, metabolic disorders (such as obesity), concomitant infectious diseases, etc. So far, the information on the effects of different comorbidities on the course of COVID-19 in children is limited, which necessitated the analysis of COVID-19 course in this cohort of patients. Key words: children, new coronavirus infection, SARS-CoV-2, COVID-19, pneumonia, multisystem inflammatory syndrome, comorbidity